{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:35Z","timestamp":1761016955626},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2001,11,27]]},"DOI":"10.1212\/wnl.57.10.1916","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:54:14Z","timestamp":1336917254000},"page":"1916-1917","source":"Crossref","is-referenced-by-count":50,"title":["No reversion in vigabatrin-associated visual field defects"],"prefix":"10.1212","volume":"57","author":[{"given":"Iiris","family":"Nousiainen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"Ma\u0308ntyja\u0308rvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetta","family":"Ka\u0308lvia\u0308inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.922"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb01599.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.6.716"},{"key":"e_1_3_2_5_2","unstructured":"Committee for Proprietary Medical Products. Opinion following an article 12 referral. Vigabatrin The European Agency for the Evaluation of Medicinal Products. CPMP-report\/1357\/99. Available at: http:\/\/www.ernea.eu.int\/pdfs\/human\/phv. 135799en.pdf."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7075.180"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.7.788"},{"key":"e_1_3_2_8_2","first-page":"40","volume":"55","year":"2000","unstructured":"Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin. Effect of stopping the drug. Neurology . 2000; 55: 40\u201345.","journal-title":"Neurology"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0397"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100720070096"},{"key":"e_1_3_2_11_2","first-page":"144.","volume":"41","year":"2000","unstructured":"Kraemer G, Ried S, Landau K, Harding GFA. Vigabatrin. Reversibility of severe concentric visual field defects after early detection and drug withdrawal: a case report. Epilepsia . 2000; 41 (suppl): 144.Abstract.","journal-title":"Epilepsia"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.57.10.1916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:25:14Z","timestamp":1711545914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.57.10.1916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,27]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,27]]}},"alternative-id":["10.1212\/WNL.57.10.1916"],"URL":"https:\/\/doi.org\/10.1212\/wnl.57.10.1916","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11,27]]}}}